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Glossary 
Term / Acronym Meaning 
A1C HbA1C – indicator of diabetic control 
Arthriter Young person who took part in the ‘Arthriting’ blog project - a name coined by the young 
people themselves. 
Arthriting The name of the previous project undertaken by this team to explore the links between 
identity, arthritis and medication use for young people with Juvenile Arthritis – this was a 
blog project involving young people and parents. This name was chosen by the young 
people’s advisory group for that project. 
BANNAR Barbara Ansell National Network for Adolescent Rheumatology 
CMS Chronic medication service – A national pharmacy service in Scotland, where a person can 
register with a pharmacy of their choice to receive pharmaceutical care. 
http://www.communitypharmacy.scot.nhs.uk/core_services/cms.html  
CPD Continuing professional development 
CYPHOF Children and Young People’s Health Outcomes Forum 
DH England Department of Health (England) 
DMARD Disease-modifying anti-rheumatic drug e.g. methotrexate 
Competence Test to determine whether a young person can consent to their own treatment 
GP General practitioner / primary care doctor 
IDDM Insulin-dependent diabetes mellitus - Type 1 diabetes 
Juvenile arthritis A range of inflammatory conditions diagnosed in young people aged less than 16 years. 
These include juvenile idiopathic arthritis and lupus. 
JIA Juvenile idiopathic arthritis 
LPF Local Practice Forum – local meeting network within RPS 
LTC Long-term condition 
MDT Multidisciplinary team 
Medicines 
Optimisation 
A person-centred approach to safe and effective medicines use, enabling people to obtain 
the best possible outcomes from their medicines (NICE, 2015) 
MEP Medicines, Ethics and Practice guide - published annually by RPS 
MO Medicines Optimisation 
MUR Medicines use review – an advanced pharmacy service, specified and commissioned 
nationally (England & Wales) where a pharmacist can consult with an individual in a 
confidential area about all their medicines. Also in operation in Northern Ireland to 
targeted groups http://www.psnc.org.uk/pages/mur.html  
NHS National Health Service 
NICE National Institute for Health and Care Excellence – officially linked to England only, but 
provides guidance and services to all the other UK home countries 
NIHR National Institute for Health Research – research funding body 
NMS New medicine service – a new advanced pharmacy service, specified and commissioned 
nationally (England & Wales) where a pharmacist can consult with an individual in a 
confidential area about a new medicine received on prescription (there is a specified list). 
This new medicine can be discussed in the context of their other medicines as well. 
http://www.psnc.org.uk/pages/nms.html  
NRES National Research Ethics Service 
NSAID Non-steroidal anti-inflammatory drug e.g. ibuprofen 
OT Occupational therapist 
PRUK Pharmacy Research UK 
RCPCH Royal College of Paediatrics and Child Health 
REC Research Ethics Committee 
RPS Royal Pharmaceutical Society – professional body for pharmacists in Great Britain 
SOP Standard operating procedure – used in pharmacy practice to standardise procedures like 
handing out prescriptions 
UNFPA United Nations Population Fund 
WHO World Health Organisation 
YP Young people (defined as people aged 10-24 for this project) 
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1. Introduction and Context 
 
1.1 Medicines Optimisation – Getting it Right for Young People 
The NICE guidance on medicines optimisation (NICE, 2015) defines the term as ‘a person-centred approach 
to safe and effective medicines use, enabling people to obtain the best possible outcomes from their 
medicines’. The Royal Pharmaceutical Society (RPS) differentiates medicines optimisation from medicines 
management by virtue of its emphasis on “outcomes and patients rather than process and systems” (RPS, 
2013: p3). The first Guiding Principle of medicines optimisation in the RPS guide is “Aim to understand the 
patient’s experience”. Existing literature about young people’s use of health services, from general practice 
and specialty care (e.g. Churchill et al., 2000; Klosterman et al., 2005; Hambly et al. 2009), indicates that 
health professionals find it difficult to communicate with, and relate to, young people. GP consultations 
have been shown to be shorter with young people than adults: in the past, GPs reported them as an 
opportunity to ‘catch up’ (Jacobson et al., 1994). We know little about pharmacists’ everyday engagement 
with young people. 
 
Pharmacists have found a greater focus on young people since the Millennium, with the establishment of 
the first emergency hormonal contraception NHS patient group direction services. There are now several 
services that help pharmacists to address adolescent public health priorities. A survey by members of our 
team (Gray & Prescott, 2013), however, showed that pharmacists are failing to take opportunities to 
provide medicines optimisation services like medicines use reviews (MURs), despite dispensing significant 
numbers of prescriptions for this age group (Table 1). 
 
 
Pharmacy service provided 
% of pharmacists reporting specified frequency of provision of 
service to young people aged 13-19 years 
Never Rarely Sometimes Often 
Dispensing prescriptions (n=143) 1.4 4.9 39.9 53.8 
Medicines Use Review (MUR) (n=135) 23.7 60.7 10.4 5.2 
Enhanced services (n=130) 3.1 22.3 29.2 45.4 
Table 1 – Pharmacists’ perception of service provision to young people aged 13-19 years (Gray & Prescott, 2013) 
 
In the aforementioned study, the majority of pharmacists (62.2%) felt ‘reasonably confident’ about 
engaging with young people, and a significant minority (30.1%) felt ‘very confident’. Pharmacies are 
accessible settings for young people, and the pharmacist – like the GP – could be a source of continuity of 
care as a young person transfers from the paediatric to adult setting. Pharmacists should consider widening 
their scope of engagement to include discussions about medicines adherence and optimisation. There are 
likely to be structural and individual factors limiting these opportunities: we need to understand these 
factors to create a vision for better care of this population that minimises barriers to care. 
 
1.2 Findings from the Arthriting Study of the Blogs of Young People 
In 2012-13, a group of 21 young people with juvenile arthritis aged 11-15 years, and 6 parents, took part in 
a study at a UK paediatric hospital conducted by our team. A bespoke website was created within which 
young people and parents could contribute blogs related to arthritis, identity and medication. A young 
person from our advisory group coined the name ‘Arthriting’. The blogs showed that different health 
services, and their providers, were important to young people and families in assisting decision-making and 
supplies of therapies (Gray et al., 2013). Rheumatology doctors, nurses and other hospital staff were 
viewed very positively in terms of their credibility, expertise and empathy: the role of the GP, however, was 
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overshadowed by doubts about their expertise in prescribing for this condition. Pharmacists were rarely 
mentioned, and even then they were not described as particularly autonomous or empathic. There was an 
isolated suggestion in an online survey of participants that they could be an information resource. Data 
from the blogs suggested that patients and parents viewed their pharmacist as a technical dispensing role. 
Moreover, they were sometimes unable to do that role without making errors that frustrated parents and 
young people alike. The errors cited involved simple matters like a difference between tablets and capsules: 
things that could be noted, and thus avoided, from an engagement like an MUR. 
 
The following (unedited) blog quote reflects a perception from a young person that the pharmacist would 
not give the prescription directly to them, so their mother had to be involved: 
“My mother helps by getting my prescription and collecting the medication from the chemist as i am 
not aloud because i am to young.” 
 
It is indeed possible that a pharmacist – presented with a prescription for certain medicines commonly 
prescribed in Juvenile Idiopathic Arthritis (JIA), like methotrexate or a high-dose NSAID – might prefer to 
give it to an adult for reasons of risk management. If, however, a young person has taken on responsibility 
for the medicine in the home, and the pharmacist denies them the right to collect their own medicine, how 
will that foster the development of their independence? Each case is different: the process of medicines 
optimisation should support and record that transition as and when it is appropriate for each young person 
/ parent pairing. Guidance from the Royal Pharmaceutical Society about collection of medicines by children 
and young people provides questions that can help pharmacists to make decisions on a case-by-case basis 
(RPS MEP July 2014, p64): we wished to explore pharmacists’ confidence in these situations. 
 
In the Arthriting report we cited two case studies; a hospital paediatric rheumatology pharmacist in 
Northern Ireland and a community pharmacist working on a University campus in Scotland. Both 
pharmacists worked with young people as their main client group; both had developed their 
communication skills with young people and parents to a high level, and were focused on providing 
medicines-related services to this age group. But they are unusual in their own respective fields, and thus 
isolated in the pharmacy network. 
 
1.3 Building a multi-disciplinary team to support young people with long-term conditions 
The Arthriting study showed that pharmacy could co-lead a young-person-centred research project with 
rheumatology professionals. It challenged the multi-disciplinary rheumatology team to think about 
medication issues, and the interface between pharmacy and the medical and nursing team. 
 
The NICE (2015) medicines optimisation guidance cited ‘professional collaboration’ as one of its key issues: 
“Medicines optimisation focuses on actions taken by all health and social care practitioners and requires 
greater patient engagement and professional collaboration across health and social care settings”. (p8) This 
proposal enabled us to examine these issues for young people’s health - both between pharmacists across 
the interface, and beyond into the adolescent rheumatology team. 
 
1.4 The Policy Context – Why Pharmacists need to Consider this Now 
The recent NICE guidance on medicines optimisation (2015) emphasised that children, adolescents and 
adults using medicines were eligible to receive medicines optimisation services. The 2013 scoping 
document for this guidance also emphasised that anywhere which received public funding, including 
independent contractor settings, will be venues for these services. 
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Our scoping review showed that there were some examples of innovative and excellent practice, but that 
those professionals are isolated. Our Arthriting young person and parent blogs revealed that the profession 
more generally is largely invisible to them. Pharmacy needs to develop a cross-sector vision for the care of 
young people with long-term conditions such as juvenile arthritis in its communities, and actively promote 
it. Pharmacists may be unclear whether key services to support medicines optimisation for young people 
can currently be employed. Some may believe that it is not possible to conduct MUR or NMS for an 
unaccompanied young person under 16, but the regulations do not prevent this if competency is 
established (Personal Communication, Alastair Buxton – PSNC, November 2013). 
 
Russell Viner, in the Chief Medical Officer’s Annual Report for 2012, said that “Caring for adolescents is 
everyone’s business” (Viner, 2013: p10). The Lancet has recently established a global commission on 
adolescent health and wellbeing, and has published two separate high-visibility series of papers devoted to 
adolescent health in the last 6 years (2007 & 2012). Voices are joining together to advocate for better 
outcomes regarding the health of young people: pharmacists must not be absent from this activity. 
Juvenile arthritis has a prevalence similar to type I diabetes, affecting 1 in 1000 children and young people 
in the UK (Symmons et al., 1996), and is an excellent exemplar for a range of long-term conditions because: 
 The drug therapy is changing rapidly (with the advent of biologics) (Kahn, 2012) 
 Some medicines used to treat juvenile arthritis (such as non-steroidal anti-inflammatory drugs, 
NSAIDs) are available over-the-counter while others are only available on prescription 
 The progression and symptoms of the condition are unpredictable and positive future health 
outcomes depend on good adherence 
 Medicines used in juvenile arthritis (including methotrexate, NSAIDs, and biologics) are associated 
with a number of safety risks if taken without good explanations and ongoing support 
 The condition is characterised by periods of remission and relapse, requiring young people to take 
medication regularly for prolonged periods even when they feel well with no functional impairment 
 
We can take insights from juvenile arthritis to inform the pharmacy contribution to the care of young 
people with a wide range of long-term conditions (Suris et al., 2004). For example, we would expect the 
principles of young people friendly services to apply to the wider population, and young people’s priorities 
regarding services and the nature of their consultations with pharmacists are likely to be similar across a 
range of conditions. 
 
In this project, we wished to explore the contribution of pharmacists to the care of a broad group of young 
people experiencing different transitions – cognitive, vocational and social. For this reason we chose the 
UNICEF/WHO/UNFPA age range for young people of 10-24*. 
 
2. Guiding Question, Aim and Objectives 
 
Guiding Question:  
What is the perceived and potential medicines optimisation role of pharmacy for young people with long-
term conditions, explored through the case study of juvenile arthritis? 
 
Aim:  
To explore the current role, the potential role, and the needs of pharmacists to deliver services to young 
people with arthritis. 
                                                          
* http://www.un.org/esa/socdev/documents/youth/fact-sheets/youth-definition.pdf  
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Objectives: 
1. To scope current knowledge and practice of pharmacists regarding young people, including those with 
juvenile arthritis; 
2. To explore the perceived and potential roles of pharmacists in the care of young people with juvenile 
arthritis, from the perspectives of community and hospital pharmacists, rheumatology health professionals 
and commissioners; 
3. To inform the development of models of care, integrating pharmacy within the multidisciplinary team, in 
order to help young people with juvenile arthritis to optimise their use of medicines. 
 
3. Methods 
 
3.1 Project Overview 
This multi-phase project was planned to build on the findings from the previous Arthriting project, and each 
phase to then build on the last (Figure 1 overleaf). Using Arthriting data as stimulus points for focus groups 
of pharmacists, it was then possible to share ideas from those pharmacists with stakeholders and – finally – 
multidisciplinary groups of pharmacy and rheumatology staff. There was an imperative to build consensus 
around key issues, and to test the validity of the emerging results with young people themselves.  
 
We recognise that pharmacy practice is increasingly subject to different commissioning structures across 
the home countries of the UK. The most relevant impact of this to our project might be the services 
through which pharmacists consult with patients about long-term medicines. In order to consider this 
increasing variation – and the sharing of good practice resulting from innovation and diversity – we aimed 
to engage stakeholders across England, Scotland, Wales and Northern Ireland. The scope and reach of the 
study did not allow exact parallels in each country across all study phases, but we aimed for reasonable 
coverage across the whole project (please see results section for further information and reflection). 
 
3.2 Ethical Approval 
NRES classified this current project as research that did not require NHS REC Approval, as it was solely 
undertaken with healthcare staff (Appendix 1). Institutional ethical approval was given by Aston University 
Health and Life Sciences Research Ethics Committee (Ref: #674) on 4th July 2014 (Appendix 2). A minor 
amendment was sought in August 2014 to add further recruitment methods and materials for the focus 
groups, which was approved on 18th August 2014 (Appendix 3). A second and final minor amendment was 
submitted to undertake an online survey, and approved on 29th September 2014 (Appendix 4). We also 
submitted the project to the research approval process for Boots Pharmacy, which is required if any Boots 
Pharmacy staff are to take part, and it was approved on 10th September 2014 (Appendix 5). 
 
3.3 Project Management 
A project team had been established for the previous ‘Arthriting’ study. Some members of this team stayed 
together to develop this follow-on work: Nicola Gray, Felicity Smith and David Terry (Academic Pharmacy); 
Janet McDonagh (Paediatric and Adolescent Rheumatology); Julie Prescott and Karen Shaw (Psychology). 
The team recognised the importance of engaging more clinicians in this next phase, and the particular 
insights of innovators in this area - Catrin Barker (Chief Pharmacist, Alder Hey Children’s Hospital), Jonathan 
Burton (Right Medicine Pharmacy, Stirling University) and Roisin Campbell (Musgrave Park Hospital, Belfast) 
joined the project team. An advisory group was also convened, with complementary skills: Alastair Buxton 
(Director NHS Services, PSNC); Dick Churchill (Academic GP / adolescent health); Janet Gardner-Medwin 
(Paediatric and Adolescent rheumatology); Manir Hussain (Pharmacy commissioning); Lamis Mullgrave 
(Young person advising the Arthriting project and this project); Catherine Wright (Advocate, Arthritis Care 
Belfast). There were combined meetings in June 14 and May 15.
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Figure 1 – Overview of the project 
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3.4 Phase 1 – Development of the Study Instruments 
In this phase, the Project Team and Advisory Group developed the draft focus group topic guide and the 
stakeholder telephone interview guide. The telephone interview guide, however, was further informed and 
validated by the emerging results of the focus groups. Project team and advisory group members met for a 
one-day workshop in Birmingham on 16th June 2014 to consolidate their ideas and orientate themselves to 
the aim and objectives of this new project. Quotes from the Arthriting study were shared at this meeting 
and members chose a number of quotes that best illustrated different issues for them. These were then 
circulated to members who could not attend for comment. The young adviser from the Advisory Group, 
who had also been an Arthriter, attended on that day.  
 
We were advised by team members beyond England that the term ‘medicines optimisation’ was an 
England-specific term. We used ‘pharmaceutical care’, on their advice, in materials (information sheets 
etc.) sent to the other home countries. 
 
3.5 Phase 2 – Focus groups with Hospital and Community Pharmacists (September 2014) 
Four focus groups of community and hospital pharmacists (mixed in each group) were convened across 
Great Britain (1 in Wales, 1 in Scotland, and 2 in England). We aimed for maximum diversity sampling to 
reflect different pharmacist characteristics in terms of: 
 length of time in practice; 
 role in practice (community locum, pharmacist manager, pharmacy owner – different hospital 
grades and seniority); 
 practice setting (different types of community pharmacies [such as independent, multiple, health 
centre, out-of-town retail park] and hospitals [e.g. teaching or other, Foundation Trust or not, 
specialist rheumatology team on-site or not); 
 perceived confidence and experience in engaging with young people about public health services 
and medicines use services. 
 
A number of recruitment strategies were employed to convene the focus groups: 
 The Local Practice Forums (LPFs) of the Royal Pharmaceutical Society that were close to the focus 
group locations were asked by the RPS team to circulate a message to their members   
 The ‘Research Ready’ community pharmacy network convened by the RPS (Gray et al., 2013c) sent 
an email alert to members 
 Pharmacists in the project team sent an email to their local networks 
 A request was posted in the Pharmaceutical Journal (28th August 2014) 
 An email was sent from local pharmacy postgraduate education facilitators in the group areas 
 An email was sent within Boots Pharmacy to pharmacists in the areas for the groups 
 
An initial email asked for expressions of interest (Appendix 6). A flyer was also developed, approved by the 
ethics committee through the first minor amendment (Appendix 7). Most of these emails were sent out by 
gatekeepers; indeed, NJG stressed to the gatekeepers not to cc: her into any circulation email so that 
people did not feel obliged to respond and she would not know anyone’s identifying details until they 
responded. Some of the original emails had the information sheet (Appendix 8) and consent form 
(Appendix 9) attached – these sheets were customised with the date and venue of the specific focus group, 
and either ‘medicines optimisation’ (England) or ‘pharmaceutical care’ (Wales and Scotland). Other emails 
just had the flyer, as we recognised that it might be better to send the study information only to those who 
expressed interest. Interested pharmacists were asked to reply direct to NJG, who supplied the information 
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sheet and consent form if they had not already seen them. A NHS permission form was also supplied for 
pharmacists in the managed sector (Appendix 10). Written informed consent was obtained for each 
participant. 
 
Focus groups were convened at a place and time suitable for the attendees, with local information from 
project team contacts. They were scheduled to last for 90 minutes. Discussions were recorded on digital 
audio. NJG moderated each group. NJG took field notes to supplement the audio recordings and 
administered the payment of participation fees (£30 per participant) and travel expenses. Pharmacists 
attending the focus group noted their demographic details and self-assessment of confidence on a 
structured pro-forma, before the session began, to help the team to monitor diversity (Appendix 11). 
 
The topic guide (Appendix 12) included the following issues: 
 Pharmacists’ experience of engaging with young people in general 
 Pharmacists’ experience of engaging with young people about medicines use and adherence 
 Pharmacists’ experience of engaging with specialist teams in secondary and tertiary care e.g. 
rheumatology 
 Perceived barriers to more engagement with young people about medicines (confidence, training, 
workload, confidentiality and consent, high risk medicines, isolation from the rest of the team) 
 Reflection upon the issues raised by young people in the Arthriting study and scoping review 
(collecting prescriptions, technical role of the pharmacist) 
 Potential for pharmacists to engage with young people and parents through MO services (using our 
case studies from Belfast and Stirling as stimuli) 
 Potential models of care and how these might complement existing service provision, both in terms 
of meeting young people's needs and operational aspects (liaison, communication referral with 
other providers 
 Support needed to realise this potential 
o What could they do now? 
o What could they do with a little support? 
o What more beyond that? 
 
A PowerPoint presentation was created, primarily to display the Arthriting quotes for the participants but 
also to provide some background about the study (Appendix 13). NJG used the topic guide and the 
presentation to fulfil the objectives of each group. Each recording was transcribed verbatim, checked and 
identifiers (names of local people or places) were removed. 
 
Phase 2 Online survey (October 2014) 
There was a small but significant number of pharmacists who wished to take part in the project but who 
could not attend the focus groups due to distance or unavailability at the date/time. Following a second 
successful minor amendment to the ethics committee, an online survey was created in SurveyMonkey™ 
software (a pdf copy generated by SurveyMonkey™ software is Appendix 14) and the link circulated to 
these pharmacists. A completion fee of £20 was offered. The survey was circulated after the focus groups 
had finished, and some preliminary analysis had taken place. 
 
The survey included the same quotes from the Arthriting data that were used in the focus group. For each 
comment the survey asked: 
 What does this comment make you think about? 
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 How could pharmacists in community and hospital practice support young people and families with 
this issue? 
 
As we were formulating the briefing for stakeholders in Phase 3 with the focus group results at this time, 
we also asked survey pharmacists to comment on what the focus groups had said about: 
 Why young people might find it difficult to take medicines 
 Challenges for community pharmacists engaging with young people 
 Challenges for hospital pharmacists engaging with young people 
 Ideas for moving forward together 
 
The SurveyMonkey™ program collated the results of the free-text comments from participating 
pharmacists, and the statistical demographic details. 
 
3.6 Phase 3 – Telephone Interviews with Adolescent Rheumatology Professionals and Other Stakeholders 
(November 2014 – April 2015) 
We proposed a series of up to 30 telephone interviews with adolescent rheumatology professionals 
(principally medicine and nursing), pharmacy policy stakeholders, and commissioners. We aimed for a 
maximum diversity sample of professionals in terms of location across the UK, gender, seniority, and their 
engagement with primary and secondary care. Ms Emma Pring (EP), the Research Assistant based with Dr 
David Terry at Birmingham Children’s Hospital / Aston University, worked with NJG in Phase 3.  
 
A sample frame of pharmacy policy stakeholders and commissioners was generated by advisory group 
members and project team. We asked for the name, role and email address of each identified stakeholder. 
We also advertised the study by email to rheumatology health professional members of the Barbara Ansell 
National Network for Adolescent Rheumatology (BANNAR). 
 
An email was sent to each suggested stakeholder to recruit participants (Appendix 15). One final follow-up 
email was sent 7 days later. Stakeholders who responded were sent an information sheet (Appendix 16) 
and consent form (Appendix 17) to obtain written informed consent. An NHS permission form was also 
available for stakeholders in the managed service (Appendix 18). Once consent had been confirmed, a 
briefing was sent to the stakeholder to give them background information about the interview and to 
provide structured prompts which would guide the interview (Appendix 19). The briefing combined the 
Arthriting results, the pharmacist case studies from the scoping review, and the pharmacist focus group 
themes. The latter came from a preliminary top-level thematic analysis of the focus group transcripts. 
 
EP and NJG each undertook telephone interviews, which were recorded on digital audio with the 
participant’s consent. The researchers also took field notes as necessary – the briefing pro-forma was 
useful for this purpose. Telephone interviews were scheduled at a time convenient for the participant, and 
scheduled to last for 30 minutes. A participation fee was available of £30 per participant for each 
completed interview. Each recording was transcribed verbatim, checked, and identifiers (names of local 
people or places) were removed. EP and NJG had regular telephone conversations about the interviews. EP 
had to finish work on the project in February 2015, and NJG took over at that point to complete Phase 3. 
 
The telephone interview schedule (Appendix 20) included issues dependent on the role of the interviewee 
(rheumatology team member RT, pharmacist policymaker PP, pharmacy staff PS or commissioner C): 
 Their current practice about medicines use and adherence – who in the team is involved, in terms of 
policy and practice? (RT, PS) 
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 Reflection upon the issues raised by young people in the Arthriting study and scoping review (collecting 
prescriptions, technical role of the pharmacist) (RT, PP, PS, C) 
 Their experience of engaging with hospital and/or community pharmacists about young people 
(positive or negative) (RT, PS) 
 Whether they could see a role for hospital and/or community pharmacy to help with their work (RT, C) 
 Potential models of pharmacy involvement (RT, PP, PS, C) 
 Perceived barriers to more engagement with pharmacists (confidence in pharmacists’ training and 
skills, workload, confidentiality and consent, high risk medicines, physical isolation of pharmacy from 
the rest of the team) (RT, PP, PS, C) 
 Ways to work together to overcome barriers (RT, PP, PS, C) 
The aim was to continue to recruit participants until data saturation was achieved (i.e. no new themes were 
emerging). 
 
3.7 Phase 4 – Consensus-building discussion groups combining pharmacists and rheumatology 
stakeholders (February 2015 – March 2015) 
We convened three multidisciplinary discussion groups of hospital and community pharmacists, each group 
joined by rheumatology stakeholders (to provide context and field queries). There were two groups in 
England and one group in Scotland. These groups considered the combined ideas from the Phase 2 
pharmacist focus groups and the Phase 3 stakeholder interviews to try and build consensus around 
pharmacy roles that would add value to their clinical practice for their patients. 
 
Three members of the project team/advisory group advised NJG, and acted as gatekeepers to prospective 
participants in their local area. Discussion with these contacts concluded that the best way to bring the 
professionals together was to work with the rheumatology staff to find a time that they might use for 
educational meetings where we could convene a discussion group at a convenient location. Pharmacists 
were then invited to these meetings. An attendance fee of £30 was offered to each participant. As these 
meetings took place during working hours, community pharmacists who wished to attend but would have 
to leave their pharmacy were offered locum backfill fees to make this possible. Travel expenses were also 
paid. Different recruitment strategies were employed for rheumatology staff and pharmacists.  
 
Pharmacists – As for Phase 2, a number of strategies were used to recruit community and hospital 
pharmacists to Phase 4: 
 The ‘Research Ready’ community pharmacy network convened by the RPS (Gray et al., 2013c) sent 
an email alert to members 
 Pharmacists in the project team sent an email to their local networks 
 An email was sent from local pharmacy postgraduate education facilitators in the group areas 
 An email was sent within Boots Pharmacy to pharmacists in the areas for the groups 
 
Some pharmacists from the Phase 4 study areas had registered their interest in the project with NJG from 
the wide distribution of information for Phase 2, and their contact details had been kept on file. 
 
An email was sent to each gatekeeper for circulation to prospective participants (Appendix 21), with a flyer 
attached that had been adapted from Phase 2 (Appendix 22). As for Phase 2, expressions of interest were 
directed to NJG, who then sent an information sheet (Appendix 23) and consent form (Appendix 24) to 
obtain written informed consent. Each information sheet was customised with the venue, date and time of 
the specific discussion group. 
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Rheumatology Staff - An email was sent to each team facilitator for circulation to prospective rheumatology 
team participants in each of three hospital paediatric rheumatology centres for whom we had a contact 
among the project team and advisory group members (Appendix 21), including an information sheet 
(Appendix 23) and consent form (Appendix 24) to obtain written informed consent. The multidisciplinary 
rheumatology team members invited included doctors, clinical nurse specialists, occupational therapists, 
physiotherapists and transition coordinators. 
 
A more structured approach was applied to these discussions, adopting some techniques of prioritisation 
and sorting deployed in nominal groups (Tully & Cantrill, 1997) but still allowing more free-flowing 
discussion if needed. Small group working was employed. The groups were not recorded. Project team 
members Janet McDonagh and Karen Shaw had developed a consensus-building tool for a previous piece of 
work (Shaw et al., 2004); the format of this tool lent itself well to our objective for a consensus-building 
session so the format was adopted for some paper-based exercises during the group work. 
 
The plan for running the groups was as follows (Appendix 25): 
 Each participant individually completed a background and context survey (Appendix 26) which 
noted some demographic details about them (including discipline, time in practice, self-reported 
confidence talking about adherence) and had some statements about pharmacy and medicines 
 Small group work (mixed of pharmacists and rheumatology team) looking at some of the Arthriting 
quotes to start a conversation – ice breaker 
 Small group work (mixed of pharmacists and rheumatology team) to assess the best practice 
prioritisation and feasibility of a number of pharmacy roles suggested primarily during the focus 
groups, but also discussed during stakeholder interviews (Appendix 27) 
 Small group work (pharmacists and rheumatology team separately) to choose a ‘top 5’ group of 
pharmacy activities / roles (Appendix 28 - statements from exercises 2 and 3, transcribed on to 
cards, and to place them on a timeline (Figure 2) to indicate by when they should be implemented  
 Each participant individually revising any responses they wish from the context survey (Appendix 
26) 
 
Figure 2 – Example of a timeline used in one of the multidisciplinary group discussion sessions 
 15 
The resulting data were thus quantitative in nature, and transferred from paper data collection forms to an 
Excel™ spreadsheet database. 
 
3.8 Data Analysis 
Data analysis in this project was dynamic as each phase built upon the previous one. Although the last few 
Phase 3 stakeholder interviews were undertaken in parallel with the Phase 4 multidisciplinary groups, 
strong broad consensus themes from Phase 2 and Phase 3 were already emerging and persisted. 
 
Analysis of Phase 2 focus groups: Focus group digital audio recordings were transcribed verbatim. 
Qualitative analytical procedures were used. A ‘middle-order’ approach (Becker and Geer, 1982) was used, 
which is consistent with ‘directed content analysis’ (Hsieh & Shannon, 2005). The study objectives provided 
a clear source of categories with which to organise participants’ responses, whilst allowing other themes to 
emerge. We were interested in differences across the home countries, and the perspectives of hospital and 
community pharmacists therein. Alongside the traditional qualitative analysis undertaken by the academic 
researchers on the team (JP, KS, FS), we also engaged clinicians on the team (JB, NG, JMcD and DT) to take 
one focus group transcript each and to list all the current and future pharmacy service developments that 
were contained therein. A summary briefing of preliminary key themes was generated shortly after the 
focus groups to inform the stakeholder interviews in Phase 3. 
 
Analysis of Phase 3 stakeholder interviews: Interview digital audio recordings were transcribed verbatim. As 
for the focus groups, qualitative analytical procedures were used. We were interested to explore 
differences across home countries, and different stakeholder groups. Detailed analysis of data for each 
theme were undertaken, to identify situational factors, experience of beliefs that potentially highlight the 
extent to, or ways in which, findings are context specific or likely to be relevant more widely. We identified 
any specific perspectives and experiences of different stakeholders interviewed, and then examined 
common themes bringing together all perspectives. At the end of Phase 3 we generated a list of statements 
linked to the emerging analysis of Phases 2 and 3 in order to underpin the prioritisation and ranking 
exercises planned for Phase 4. 
 
We undertook thematic analysis of the pharmacist focus groups, and the stakeholder interviews, and 
described any new - or modified current - aspects of care that have emerged as ideas therein. We will 
undertake further analysis - as part of underpinning feasibility work for a further NIHR grant application - to 
describe them in terms of their input/resource, activities/process and outputs/impact. 
 
Analysis of Phase 4 multidisciplinary discussion groups: These structured groups followed accepted 
procedures which involve a process of prioritisation. This drew primarily on quantitative ranking methods. 
Further qualitative analysis to identify potential barriers and opportunities regarding different aspects of 
care will form part of the underpinning work for the next grant. This will enable the project team and 
advisory group to select some novel care strategies to pursue in terms of providing educational support for 
pharmacists and designing an intervention. 
 
3.9 Patient and Public Involvement  
Two meetings took place towards the end of the project to engage our young advisers from the previous 
Arthriting project, and young advisers working with Arthritis Care, to comment upon the themes coming 
from the pharmacists and other stakeholders in the project. One group took place in England; the other in 
Northern Ireland. 
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No assumptions were made about the baseline knowledge of pharmacists held by the young people in the 
session. We assumed that they would have low awareness and expectations of community and hospital 
pharmacists as reported by the participants in the previous Arthriting Project. The session plan (Appendix 
29) was as follows: 
 Explore any previous contact with pharmacists in community or hospital settings; 
 Ask young people for comments about: 
o Pharmacists’ perceptions of their challenges when taking long-term medication 
o Challenges for community pharmacy in engaging with young people 
o Challenges for hospital pharmacy in engaging with young people 
o Ideas for better engagement with young people 
 
4. Results 
 
As the project was conducted so that each layer of data collection and analysis was informed by the 
previous phase, preliminary results reported here will focus on the final consensus-building timeline activity 
within the Phase 4 multidisciplinary discussion groups will illustrations of the associated underpinning 
qualitative data from the preceding phases. Further in-depth analysis of each of the Phases will be reported 
- following peer review - in academic papers from this project. 
 
4.1 Project Participants 
Our methodological imperative was to include a diverse group of pharmacists and other stakeholders in the 
project (Table 2). We believe that we achieved this.  
 
Phase 2 Focus Groups 18 Pharmacists (4:4:4:6) 
7 hospital: 10 community: 1 hospital / public health 
4 Wales: 4 Scotland: 10 England 
Phase 2 Survey 5 Pharmacists 
4 community: 1 hospital 
1 Wales: 4 England 
Phase 3 Stakeholder Interviews 15 Stakeholders 
3 pharmacist commissioners 
2 pharmacist policymakers 
2 pharmacy staff members (1 community and 1 hospital) 
4 rheumatologists 
1 specialist nurse 
3 lay advocates 
1 Northern Ireland: 1 Scotland: 13 England 
Phase 4 Stakeholder Discussion 
Groups 
26 Participants (11: 8: 7) 
13 pharmacists; 13 rheumatology staff 
9 community pharmacists 
4 hospital pharmacists 
7 rheumatologists 
5 specialist nurses 
1 physiotherapist 
8 Scotland: 18 England 
PPI work with young people 20 participants (13: 7) 
7 Northern Ireland: 13 England 
Table 2 – Participants in each phase of the project 
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The pharmacists in Phases 2 showed diversity in terms of many attributes including gender, time in 
practice, pharmacy ownership/type and practice setting (Table 3). 
 
Attribute Community (n=9) n Hospital (n=9) n 
Gender: 
 
 
Time in Practice: 
 
 
 
 
 
Pharmacy Owner / Type: 
 
 
 
 
Setting (Community): 
Male 
Female 
 
Less than 1 year 
1-5 years 
6-10 years 
11-20 years 
21+ years 
 
Local 2-5 stores 
Regional > 10 
National > 100 
Missing 
 
Village 
Local Neighbourhood Shops 
Suburban High Street 
University Campus 
 
5 
4 
 
2 
1 
1 
3 
2 
 
1 
3 
4 
1 
 
4 
1 
3 
1 
Male 
Female 
 
Less than 1 year 
1-5 years 
6-10 years 
11-20 years 
21+ years 
 
Medium 
Large 
Small Foundation 
Large Foundation 
Missing 
 
 
5 
4 
 
0 
2 
2 
2 
3 
 
1 
1 
2 
3 
2 
Table 3 – Demographic and practice characteristics of Phase 2 focus group pharmacists 
 
4.2 Self-reported confidence and expertise 
Pharmacists in Phase 2 were asked to gauge their confidence and skills in working with young people 
(Figure 3 overleaf). There was some diversity in the sample; only one pharmacist rated themselves 10 for 
any of these attributes, and one pharmacist rated their communication skills as low as 3.  
 
The median value and range for each aspect of personal practice was 8 (5-10) for confidence; 7 (3-9) for 
skills and 7 (4-10) for knowledge. 
Figure 3 – Box plot showing self-reported confidence, skills and knowledge when engaging with young people in 
consultations among Phase 2 focus group pharmacists (1 is low; 10 is high) (17 pharmacists – 1 response missing) 
10 
 
   8 
 
   6 
 
   4 
Score 
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Pharmacists and rheumatology staff in Phase 4 were asked to gauge their own knowledge about 
rheumatology medicines and MO/adherence; general medicines and MO/adherence; and generic young 
people’s health issues, such as sexual health (Table 3). Community pharmacists reported a lower median 
knowledge score regarding rheumatology-specific MO than the other professional groups, while 
community and hospital pharmacists reported the highest median score for general MO and generic young 
people’s health issues. Community pharmacists showed the widest range of rating for their knowledge of 
generic young people’s health issues, from 1-5 among the group.  
 
 
 
 
Knowledge Topic 
Professional Group (n=)  
Median (Range) : 1 is low; 5 is high 
Clinical Nurse 
Specialists 
(5) 
Paediatric 
Rheumatologists 
(6) 
Community 
Pharmacists 
(9) 
Hospital 
Pharmacists 
(4) 
Medicines optimisation / medication 
adherence in rheumatology 
3 
(3-4) 
4 
(2-4) 
2 
(1-3) 
3 
(all 3) 
General medicines optimisation and 
medication adherence 
3 
(2-4) 
3.5 
(1-4) 
4 
(2-4) 
4 
(3-5) 
Generic young people’s healthcare 
issues, such as sexual health 
3 
(3-4) 
3.5 
(3-4) 
4 
(1-5) 
4 
(1-4) 
Table 4 – Self-reported knowledge score among discussion group participants about MO and young people’s health 
 
4.3 Issues prioritised during consensus-building 
Table 4 on the following page shows the support among rheumatology (Rh) and pharmacy (Ph) members, 
in each of the three multidisciplinary discussion groups, for different services.  
 
The development of communication skills with young people and parents among pharmacists 
A strong theme throughout the groups was the need for pharmacists to develop skills in talking to young 
people and parents. Rheumatology staff emphasised that these extend beyond understanding 
confidentiality and consent – which pharmacists are becoming familiar with through provision of public 
health services such as emergency contraception. 
I think there are a specific set of skills, communication skills - which were over and above sort of 
understanding confidentiality - which are often the barrier to why people don’t engage with young 
people well. [SK33, Rheumatologist, England] 
 
These skills included: gauging the level of engagement of the young person with conversations about 
medicines; managing the input of parents without excluding them, and tailoring information in a 
developmentally-appropriate way. Most pharmacists were not trained to do this, and many learned by 
experience. A major barrier identified to developing these skills in community was the lack of opportunities 
to engage with young people directly, as their parents tended to collect their prescriptions. 
 
Information flow between sectors 
Participants throughout the work, from all backgrounds, showed strong consensus about the need for 
better information flow between pharmacists in the community and pharmacists in the multidisciplinary 
hospital team. One area often cited was the sourcing of ‘specials’ by community pharmacy: 
I think communication from our part is really important - from the hospital going back into community 
as well. So, with us, anything unusual which comes in tablet or capsule form, which is very difficult to 
obtain in the community, we send out the patient with a letter which gives them all the information 
where we’ve ordered the preparation from, so that you guys in the community don’t have an issue 
obtaining it. [P03, Hospital Pharmacist, England] 
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Statement of Current / Future Service Group (Rheumatology Rh & Pharmacy Ph) 
Rh1 Rh2 Rh3  Ph1 Ph2 Ph3 
Pharmacists develop better skills in communicating with young people and parents. Today       By 
2016 
Hospital pharmacists do medication review for young people with JIA.  Today Before 2016      
Hospital pharmacists do clinics in the community for young people with JIA.  By 2016    By 2017   
Hospital pharmacists do continuing professional development sessions for community 
pharmacists about JIA medicines. 
      By 2016  
Hospital pharmacists are included in MDT sessions for rheumatology patients. Today  By 2016     By 
2016 
Rheumatology team members do continuing professional development sessions for 
community pharmacists about JIA medicines. 
2016        
Community pharmacists co-ordinate supply of JIA medicines for young people.      Today   
Community pharmacists support young people by developing their general healthcare 
skills e.g. repeat prescriptions, getting free prescriptions. 
By 2016 By 2016 By 2016      
Pharmacists work with Healthcare at Home to optimise medicines supply.  H only - 
Today 
Today      
Pharmacists are advocates for young people with JIA and challenge prescribing decisions.  Today       
Pharmacists develop specialist expertise in paediatric/adolescent rheumatology. Today H only - 
today 
H only - 
Before 2016 
  2016   
Pharmacists develop specialist expertise in young people’s medication use for other 
long-term conditions (asthma, diabetes). 
       By 
2016 
Young people with JIA carry a card to signal their condition and their ability to collect 
their own prescriptions. 
     By 2018 2016 Today 
Pharmacists share information with young people about apps and websites that support 
adherence and give information about JIA. 
 By 2017    By 2018 By 2016  
Pharmacists facilitate young people’s self-advocacy skills (e.g. decision-making, effective 
communication, disclosure). 
      By 2018  
Information supplied by hospital pharmacists at discharge goes directly to a nominated 
community pharmacist as well as the GP. 
 Before 
2016 
   2016 Outpts by 
2018 
Today 
Pharmacists support transition services for young people going into adult rheumatology 
care. 
 2016     2017  
Pharmacists provide educational sessions for the multidisciplinary rheumatology team 
about medicines optimisation. 
 H only 
before 
2016 
      
Table 5 – Results of the timeline prioritisation activity in Phase 4 discussion groups 
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It was apparent, however, that community pharmacists recognised their lack of knowledge about specialist 
areas like JIA and really wanted a pharmacy contact within the hospital to whom they could turn with other 
specialist clinical queries. Community pharmacists suggested that educational sessions run by local hospital 
pharmacists on such topics might then result in an ongoing relationship, with the hospital pharmacist as a 
known point of contact for future queries. 
 
Pharmacists developing specialist expertise 
Development of specialist expertise among pharmacists was a major discussion topic across all phases of 
the project. It was recognised that community pharmacists were unlikely to develop specialist knowledge 
about a range of areas. Although some might become a pharmacist with a special interest in one area, 
participants felt that it was more workable to develop the specialist role of the hospital pharmacist and 
then for community colleagues to be able to call on them for advice. It was recognised, however, that 
hospital pharmacists were often expected to cover a number of different paediatric specialties and this 
limited their integration into any multidisciplinary team (MDT): 
if a pharmacist is dealing with patients with such rare conditions - such unusual conditions - how 
many of these kind of conditions does a pharmacist need to be involved with in order to maintain 
those skills?...Maybe there need to be designated people, within a group of community pharmacists, 
who perhaps specialise in these sorts of treatments and conditions. [SK26, Rheumatologist, England]  
 
Integration of hospital pharmacists within the rheumatology MDT 
Despite the service pressures noted in the previous section, the specialisation discussions reached a broad 
consensus point that the hospital pharmacist should be better integrated within the rheumatology MDT. 
Some rheumatology stakeholders described innovative examples of working that were hitherto unknown to 
the project team, including a move to pharmacist prescribing in a paediatric rheumatology clinic: 
I’ve moved in my experience as a doctor…from the frustration of the junior doctor with the green 
writing on the medicines card…To viewing pharmacists as being a fantastic resource…The other thing 
I should just say is that actually we “use” our pharmacists as well to do repeat prescribing for patients, 
so our pharmacist does repeat prescribing for stable patients on methotrexate for example.              
[SK33 Rheumatologist, England] 
The project team stressed to rheumatology colleagues that we were not trying to ‘sell’ pharmacy when we 
discussed possible value from pharmacy input. Their reflections following this declaration, however, still 
resulted in their feeling that pharmacy input would be appreciated as a complementary role to clinical 
nurse specialists. 
 
Pharmacists co-ordinating supplies of medicines 
Despite the relatively low prevalence of juvenile arthritis in the average community pharmacy practice, 
there were specific reports of help that community pharmacists were giving in co-ordinating supplies of 
medicines - this example was from a hospital pharmacist who had practised in community pharmacy: 
I have come across one young person with arthritis, and did speak to that patient, but I would say he 
was an adolescent and he was having certain problems with medication…I can say there were issues 
of specific formulations and allergies…It took 7 months actually to resolve, in the end, but we did find 
a particular make that the patient found suitable and acceptable and did, as far as I’m aware, carry 
on taking his medicine, to the best of my knowledge. [P09 Hospital/Public Health Pharmacist, Wales] 
There was also a significant amount of discussion about the advantages and disadvantages of home care 
delivery services, nurse-led initiatives which were used widely for subcutaneous injection products. Many 
young people might be accessing medicines for their JIA through several channels; hospital / home care for 
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the biologics or methotrexate injections, and their GP / community pharmacist for non-steroidal analgesia. 
Good communication was needed. 
 
Empowerment of Young People 
One of the most interesting findings in the final discussion groups was that all the rheumatology teams 
prioritised the role of community pharmacy in developing ‘general healthcare system’ skills, whilst none of 
the pharmacy groups did so. These skills might include helping young people to understand and navigate 
the repeat prescription service in general practice, and helping them to minimise prescription charges as 
they move out of full-time education to work. It is unclear whether the pharmacists either assumed it was 
part of their core activity, or whether it did not seem aspirational enough as a role: 
I think - if nothing else – it (consultation)’s just an opportunity to spend a small portion of protected 
time with a patient, and almost just impress on them what way you can help. So it’s part medication 
review and it’s part education about the service - that’s sort of the way that I approach it.            
[P17 Community Pharmacist, Scotland] 
There was also significant discussion across all phases of the project about the challenge in facilitating self-
management among young people with regard to collection of prescriptions. Pharmacists in the focus 
groups – in both hospital and community settings - spoke at length about the challenge of knowing when a 
young person was ready to take on that responsibility, and their own responsibility/liability: 
It is in the SOPs that it is over 16s; it is in the procedure, so I think that is where the fear factor comes 
from. So once you break procedure, then even indemnity insurance and things have implications, so 
that like could be an issue. [P11 Community Pharmacist, England] 
There was consensus that pharmacists had to revisit their prescription collection policies (enacted through 
Standard Operating Procedures, SOPs) to enable relationships to develop where an empowered young 
person could collect their medication themselves. 
 
4.4 Reflections of Young People in the Advisory Groups 
As anticipated by the project team, young people with juvenile arthritis in England did not have much 
engagement with pharmacists. If they needed information about their medicines, they reported that they 
would primarily ask a parent – who they recognised might then speak to a pharmacist or doctor on their 
behalf. Frustration about dispensing mistakes was reported. Young people agreed with themes that 
pharmacists did not know how to talk to young people, and tend to direct their conversation at parents; 
that community pharmacists did not have specialist knowledge about JIA, and that hospital pharmacists are 
too busy to talk. 
 
In Northern Ireland, however - where there is a dedicated paediatric rheumatology pharmacist – there 
were more reports of useful advice and engagement with hospital pharmacy. Awareness of, and confidence 
in, community pharmacy remained low. 
 
5. Discussion 
 
In February 2013, the DH England system-wide response to the report of the Children and Young People’s 
Health Outcomes Forum (CYPHOF) created a board, jointly chaired by the Chief Pharmaceutical Officer and 
the President of the RCPCH, to develop a programme to optimise the use of medicines in children. This 
included an objective to improve workforce capacity and capability (DH England, 2013: p36). This project 
has helped to elicit how to increase the capacity, capability and confidence of pharmacy staff. 
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It is an excellent time for pharmacists to reflect on the current and potential roles that they have in the care 
of young people with long-term conditions: this project has offered the opportunity for the profession to 
do that, and then to identify the support that they will need to make changes to their practice with 
confidence. 
 
5.1 Strengths and Limitations of the Project 
This project was successful in engaging a broad range of participants across the UK. There was enthusiasm 
and interest in the topic from the pharmacists, rheumatology stakeholders and young advisers. It has 
provided a wealth of information and ideas to inform pharmacy practice development. We acknowledge 
the limitations of the project, however. Inevitably the participants in the group discussions and interviews 
will be among those most positive about these issues. It was very difficult to engage stakeholders beyond 
England in our interviews, which was frustrating as we tried hard to dispel an ‘England-only’ perspective. 
We believe, however, that there was sufficient diversity of participation in each of the home countries to 
be able to say something insightful about the impact – and, indeed, opportunities – of devolution. 
 
5.2 Future Work 
This project team started by exploring young people’s perspectives of medicines and pharmacy services. 
This project has added the perspective of the pharmacist and rheumatology team and commissioners. Now 
completed, these two studies underpin the robust development and testing of one or more enhanced 
models of care - for a wider range of long-term conditions - that will go forward for NIHR intervention 
funding in 2016/17. We believe that there are certain components of pharmacy practice, such as 
communication skills and risk management, where great improvements are possible to enhance medicines 
optimisation for this important – yet often overlooked - patient group. 
 
At the end of the project, we believe we have fully addressed the study aim and objectives. We had also 
hoped to address each of the following issues for current and future proposed roles.  
 
1. Describe each current and potential role in terms of the necessary resources, processes and desired 
outcomes. 
2. Map the support needs of each proposed role. 
3. Explore the acceptability and feasibility of the proposed roles with other professionals in the clinical 
rheumatology team. 
4. Explore the acceptability of the proposed roles with the young advisers on the previous Arthriting 
advisory group, and young advisers associated with Arthritis Care. 
5. Reflect upon the wider applicability of arthritis-focused services for young people with other long-term 
conditions. 
 
We believe that we have addressed issues 3-5 in some detail, and that we have started to explore issues 1 
and 2. The latter will be further developed as we move towards the intervention study proposal. 
 
6. Conclusion 
As a multidisciplinary project team, we seek better clinical outcomes for young people taking medicines for 
a long-term condition. We support the principles of the NICE Guidance for Medicines Optimisation, and 
specifically that young people should be supported to make their own decisions about their medicines. 
Juvenile arthritis is a very good exemplar of the challenges and opportunities associated with pharmacy and 
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its potential to add value to existing practice for young people with a range of long-term conditions. Many 
of the existing challenges are rooted in communication and interfaces. Other challenges come from the 
organisational context and culture of health care delivery.  
We believe that pharmacists and other members of the pharmacy team can help young people to achieve 
optimal use of medicines as an integrated part of the multidisciplinary team. Young people may not be 
aware of the possible contribution of the pharmacist to their care. They should be better-informed about 
the pharmacist’s skills and training. The point of dispensing, especially of a new medicine on prescription, 
provides an excellent opportunity to develop a relationship between a pharmacist and a young person. 
Parents should be encouraged to visit with their son/daughter to maximise that opportunity. The concerns 
and involvement of young people with their medicines will change over time as they navigate the physical 
and psychosocial developmental changes of adolescence. The medicines optimisation process has to 
recognise this, and build in more points for revisiting information and facilitating independent medicine-
taking. 
 
7. Recommendations for Stakeholders 
The project team recognises that a number of stakeholders have to play complementary roles for young 
people to be able to derive value from the expertise of the pharmacist. At a joint project team and advisory 
group meeting on 7th May 2015, the combined group considered the data from the project and devised a 
series of recommendations that would build on the main themes from the research. 
Our recommendations are grouped for four stakeholder groups: pharmacists; the wider healthcare team; 
health policymakers, and young people and families. 
For Pharmacists 
 Build communication skills and confidence with young people and their families 
 Understand the specific demands for a young person in the context of their health and health care 
and ongoing everyday life 
 Recognise that information from specialist teams may be needed as part of the clinical check 
 Build confidence in taking consent from young people in order to properly offer services like 
Medicines Use Review, and revise policies to allow collection of prescription medicines by ‘expert’ 
young people 
 Adopt the principles of ‘young people friendly services’ like the ‘You’re Welcome’ framework (DH 
England, 2011) and Walk the Talk (NHS Health Scotland: www.walk-the-talk.org.uk ) 
 Involve the whole pharmacy team in this process 
 
For the Wider Healthcare Team 
 Meaningfully integrate the pharmacist within your culture and processes 
 Routinely document a nominated community pharmacy where copies of information can be 
channelled, with the consent of the young person  
 Ensure that information flows to the nominated community pharmacist about specialist medicines 
 Ensure that community pharmacists have a point of contact in the hospital MDT for medication 
queries 
 Raise awareness with young people and families in transition programmes that the pharmacist is 
available to them, and can help them with general health system skills and their medicine queries 
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For Pharmacy / Healthcare Policymakers 
 Improve education for pharmacists (at undergraduate and post-qualification stages) about young 
people’s health, and how adolescent development impacts upon medicine-taking and decision-
making 
 Include young people’s health in foundation and advanced practice frameworks 
 Give further guidance about consent for medicine-related activities to facilitate more engagement 
 
For Young People and Families, and their Advocates 
 Think about pharmacy as a medicines information resource 
 Build a relationship with a local community pharmacist who can help you with your medicines 
 Agree a process for independent prescription ordering and collection with your pharmacy team 
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